Geron Corporation (GERN) has been under a strong bear grip, hence the stock is down -0.99% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.55% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.99% in the last 1 week, and is up 1.47% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Geron Corporation (NASDAQ:GERN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.73 and $2.72 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.78. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.76, notching a gain of 1.85% for the day. The total traded volume was 1,324,367 . The stock had closed at $2.71 on the previous day.
The stock has recorded a 20-day Moving Average of 2.93% and the 50-Day Moving Average is 0.72%. Geron Corporation is up 3.37% in the last 3-month period. Year-to-Date the stock performance stands at -42.98%.
Geron Corporation (GERN) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $10 and the lowest price target forecast is $6. The average forecast of all the analysts is $7.5 and the expected standard deviation is $2.18.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.